We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.

Ad hoc announcements pursuant to Art. 53 LR

PolyPeptide Group announces the exercise of the full over-allotment option

5 May 2021 - PolyPeptide Group AG ("PolyPeptide" or "the Group"), a global leader in peptide development and manufacturing, today announced that the Joint Global Coordinators have exercised in full the over-allotment option granted in connection with its Initial Public Offering (the "IPO") at the offer price of CHF 64 per share.

Read more